China Shineway Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
China Shineway Pharmaceutical Group has a total shareholder equity of CN¥7.3B and total debt of CN¥330.0M, which brings its debt-to-equity ratio to 4.5%. Its total assets and total liabilities are CN¥9.9B and CN¥2.5B respectively. China Shineway Pharmaceutical Group's EBIT is CN¥944.7M making its interest coverage ratio -5.7. It has cash and short-term investments of CN¥6.2B.
Key information
4.5%
Debt to equity ratio
CN¥330.00m
Debt
| Interest coverage ratio | -5.7x |
| Cash | CN¥6.23b |
| Equity | CN¥7.34b |
| Total liabilities | CN¥2.55b |
| Total assets | CN¥9.88b |
Recent financial health updates
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Financial Position Analysis
Short Term Liabilities: 2877's short term assets (CN¥8.5B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 2877's short term assets (CN¥8.5B) exceed its long term liabilities (CN¥113.0M).
Debt to Equity History and Analysis
Debt Level: 2877 has more cash than its total debt.
Reducing Debt: 2877's debt to equity ratio has increased from 0% to 4.5% over the past 5 years.
Debt Coverage: 2877's debt is well covered by operating cash flow (356.2%).
Interest Coverage: 2877 earns more interest than it pays, so coverage of interest payments is not a concern.